70946-43-9

Usage

InChI:InChI=1/C7H9NO3/c1-10-7(9)6(8)5-3-2-4-11-5/h2-4,6H,8H2,1H3

Upstream product

• 869556-74-1 methyl 2-(furan-2-yl)-2-(methoxyimino)acetate 
• 65866-86-6 2-(furan-2-yl)-2-(methoxyimino)acetic acid 
• 1467-70-5 furan-2-yl-oxo-acetic acid 
• 113452-72-5 (RS)-methyl 2-(benzyloxycarbonylamino)-2-(furan-2-yl)acetate 
• 157991-73-6 methyl alpha-(hydroxyimino)-2-furanacetate 
• 869556-76-3 methyl 2-amino-2-(furan-2-yl)acetate hydrochloride 

Downstream Products

• 869556-76-3 methyl 2-amino-2-(furan-2-yl)acetate hydrochloride 
• 321596-55-8 methyl 4,6-dibromo-3-hydroxypyridine-2-carboxylate 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF 3-HYDROXYPICOLINIC ACIDS

4,6-Dibromo-3-hydroxypicolinate esters are prepared from furan-2-yl aminoacetates in one chemical step by use of a bromination-rearrangement reaction.

Merging the structural motifs of functionalized amino acids and α-Aminoamides: Compounds with Significant Anticonvulsant Activities

Functional amino acids (FAAs) and α-aminoamides (AAAs) are two classes of antiepileptic drugs (AEDs) that exhibit pronounced anticonvulsant activities. We combined key structural pharmacophores present in FAAs and AAAs to generate a new series of compounds and document that select compounds exhibit activity superior to either the prototypical FAA (lacosamide) or the prototypical AAA (safinamide) in the maximal electroshock (MES) seizure model in rats. A representative compound, (R)-N-4′-((3′′-fluoro) benzyloxy)benzyl 2-acetamido-3-methoxypropionamide ((R)-10), was tested in the MES (mice, ip), MES (rat, po), psychomotor 6 Hz (32 mA) (mice, ip), and hippocampal kindled (rat, ip) seizure tests providing excellent protection with ED50 values of 13, 14, ～10 mg/kg, and 12 mg/kg, respectively. In the rat sciatic nerve ligation model (ip), (R)-10 (12 mg/kg) provided an 11.2-fold attenuation of mechanical allodynia. In the mouse biphasic formalin pain model (ip), (R)-10 (15 mg/kg) reduced pain responses in the acute and the chronic inflammatory phases.

NOVEL FUSED HETEROCYCLES AND USES THEREOF

This invention relates to novel compounds having the Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of H. pylori infection.

Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents

The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: The invention also relates to a process for the preparation of these compounds, as well as their use as medicaments, in particular as anti-bacterial agents.